American Society of Hirudotherapy

Leech / LSE Flap-Survival VEGF Induction (Rat)

Dorsal random skin-flap rat model: medicinal leech application + leech saliva extract injection both increase VEGF, neovascularisation + reduce necrosis vs control — Ünal 2025.

Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Dorsal random skin-flap rat model: medicinal leech application + leech saliva extract injection both increase VEGF, neovascularisation + reduce necrosis vs control — Ünal 2025.
Evidence level
Preclinical (animal)
Drug vs leech
Whole medicinal leech
Safety domains
Bleeding · Aeromonas infection · Tissue failure

Clinical translation limit

Rat dorsal-flap model results do NOT translate directly to human microsurgical flap salvage outcomes. The K040187 device clearance covers venous-congestion flap salvage; novel saliva-extract-injection routes are NOT cleared by FDA and have unknown safety profile in humans.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Source species
Hirudo verbana / medicinalis (whole-leech + saliva extract)
Discovered
2025 · Ünal K et al.
Leech / LSE Flap-Survival VEGF Induction (Rat) molecular structure

Biological Targets

  • VEGF-induced neovascularisation; epithelial regeneration; granulation tissue thickness

Key Citations

  1. Ünal K et al. (2025), J Complement Integr Med · PMID 40968464

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.